Psoriatic onychodystrophy — modern treatment trends

Objective — to conduct an in-depth search of foreign and national literary sources, in particular, reports about the results of randomized controlled clinical trials regarding the use of local combination drugs for the treatment of psoriatic onychodystrophy. The focus is on both short-term and long-term therapeutic effects, as well as minimizing the side effects. Materials and methods. We conducted the analysis of the world experience of using the local combination drug Onychocid® Emtrix for the treatment of psoriatic onychodystrophy and minimization of side effects by searching for data (2010—2021) in the Cochrane Library controlled tests by keywords: psoriasis, onychodystrophy; in PubMed, High Wire Press, Google Scholar — by terms of the catalog and medical subjects: psoriasis + onychodystrophy + treatment; reports of randomized controlled clinical trials, meta-analyses and literature reviews. Results and discussion. The modern view on the problem of psoriatic onychodystrophy, methods and approaches to the treatment of this pathology are presented.According to the analysis of the results of foreign and national studies, Onychocid® Emtrix is proved to be clinically efficient and safe as complex treatment for various clinical forms of psoriatic onychodystrophy. It contains a combination of propylene glycol, urea and lactic acid. Active substances, which are part of the drug, are synergists, which provides triple action of ingredients — combining moisturizing and keratolytic effects with antifungal properties. Most patients showed an early (in the 2nd to 4th week of use of the drug) improvement in the appearance of the affected nails. In the future, they observed thinning of nail plates, color restoration, disappearance of excessively keratinized nail tissue, tendency to the restoration of the integrity of nails. The use of this topical medication provided high compliance due to an excellent profile of tolerance and the possibility of application once a day. Conclusions. It has been proven that the modern medication of local action Onychocid® Emtrix is currently the most optimal treatment for psoriatic onychodystrophy which allows achieving a therapeutic effect both in monotherapy and in the standard complex schemes. Treatment of psoriatic onychodystrophy with Onychocid® Emtrix is more effective in comparison with standard therapy, contributes to a rapid partial or full restoration of the integrity of nail plates. The high effectiveness and safety of Onychocid® Emtrix give reason to recommend it for inclusion in the schemes of complex treatment of patients with psoriatic onychodystophy.